GenFleet Therapeutics (2595.HK) announced the Company will be included into the eligible shares list of the Stock Connect from today (including Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect) according to publishments of the Shanghai Stock Exchange and the Shenzhen Stock Exchange.
The Company will also be included as a constituent of Hang Seng Index Series starting today, including the Hang Seng Composite Index (HSCI), Hang Seng Stock Connect Hong Kong Index, and Hang Seng Innovative Drug Index, according to the quarterly review results published by Hang Seng Indexes Company Limited in Feb. 2026.
Additionally, the Company has been included as a constituent of the MSCI Global Small Cap Index, according to the quarterly review results announced by Morgan Stanley Capital International (MSCI), with the adjustment taking effect after the close of trading on Feb. 27, 2026.
“The inclusion of the company’s shares into into the Stock Connect program, along with the entry into multiple major indices, represents a significant enhancement of GenFleet’s capital market profile and reflects investors’ recognition of our sustained value and potential. The inclusion into the Stock Connect program will further improve our stock liquidity, broaden our investor base with diversified shareholder composition, and support our development in the long run.”stated Qiang Lu, Ph.D., Chairman of GenFleet.
GenFleet submitted the A1 application in December 2024 and was successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEX) in September 2025. It was the only HKEX 18A-listing with the Company already possessing a launched innovative therapy (fulzerasib) as well as out-licensing revenue from domestic and overseas partnerships. The cornerstone subscriptions and the gross proceeds after the exercise of the over-allotment option both set records in IPO fundraising under Chapter 18A rule since 2022.
Currently GenFleet has established a leading position in RAS-targeted therapeutics, with its RAS-focused pipeline encompassing fulzerasib as China’s first approved KRAS G12C inhibitor, GFH375 as the world's first phase-III oral KRAS G12D inhibitor, GFH276 as the third Pan RAS inhibitor globally entering clinical development and GFS784 as the world's first Pan RAS ADC with accepted IND submission. Building on this synergistic portfolio, GenFleet is advancing treatments in major therapeutic areas such as pancreatic cancer, non-small cell lung cancer, and cachexia.
The Hang Seng Composite Index, as a comprehensive H-share benchmark, covers the top 95% of listed companies by cumulative market capitalization on the HKEX Main Board and is widely used by index funds, mutual funds, and performance evaluation systems. Leveraging its proven expertise and sustained value creation, GenFleet will strengthen its first-tier development of RAS-targeted therapeutics and the competitiveness in developing other innovative treatments, to expand its market presence while advancing corporate responsibilities to patients and society.
